Strategic Intelligence Report
Generated July 29, 2026
Enterprise Software
Omnicell
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Fremont, California, USA
Website
Employees
4,000 (2026, approximate)
Founded
1992
Listing
OMCL · NASDAQ
Market Cap
$1.89B
Revenue (TTM)
$1.23B
Price
USD41.49 (-8.25%)
Market data as of Jul 28, 2026, 11:21 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
Omnicell is a healthcare automation and pharmacy technology company providing medication management systems and software used by hospitals and pharmacies, anchored in a strategy of driving autonomous medication management via its cloud-native OmniSphere platform. Q1 2026 total revenue reached $310 million, up 15% year-over-year (20% product growth), with EPS beating estimates and non-GAAP EBITDA up 88%; the company booked its first Titan XT Automated Dispensing System orders in the quarter and maintained full-year 2026 revenue guidance of $1.215-1.255 billion.
Strategic Connections
Competition / Other
- Diebold Nixdorf: Omnicell operates in the broader automated retail and dispensing hardware category, adjacent to self-service hardware providers like Diebold Nixdorf.
- Cloud Computing & Data Centers: Omnicell provides healthcare automation software and hardware within the broader cloud computing and enterprise technology industry.
Strategic Risks
- Hospital and pharmacy capital equipment purchasing cycles can be sensitive to healthcare provider budget constraints
Future Outlook
- Continued growth expected from hospital automation and medication safety compliance demand
- Raised full-year 2026 EBITDA guidance reflects management confidence in sustained demand and cost discipline
Sources
- BusinessWire (Apr 2026) — Omnicell Q1 2026 revenue grows 15% to $310M
- Omnicell corporate site (Jan 2026) — Omnicell corporate overview
- StockTitan / Benzinga (Apr 2026) — Omnicell Q1 2026 EPS beats forecast, raises full-year EBITDA and EPS guidance
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.